Absci reports Phase 1 safety data for hair loss antibody ABS-201

June 24, 2026 6:30 AM

Absci Corporation (Nasdaq: ABSI) reported interim Phase 1 data from its first-in-human HEADLINE trial of ABS-201, an investigational antibody targeting ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found